AZD5851

BIOLOGICAL2 trials

Sponsors

AstraZeneca

Conditions

Hepatocellular CarcinomaProstate Cancer

Phase 1

A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma

Active, not recruitingNCT06084884

AstraZenecaHepatocellular Carcinoma

Start: 2023-12-14End: 2027-12-13Target: 94Updated: 2026-08-19

Unknown Phase

LTFU for All Cell and Gene Therapy Studies

Not yet recruitingNCT06194461

AstraZenecaHepatocellular Carcinoma, Prostate Cancer

Start: 2025-09-17End: 2041-11-29Target: 64Updated: 2025-06-27

Related Papers

Abstract 4826: Tyrosine kinase inhibitor combination therapies with AZD5851, dominant-negative TGFβRII armored anti-GPC3 CAR-T, for the treatment of hepatocellular carcinoma

Cancer Research2025-04-21

ATHENA: A phase 1/2 study of AZD5851, a chimeric antigen receptor (CAR) T-cell therapy directed against GPC3 in adult patients with advanced/recurrent hepatocellular carcinoma (HCC).

Journal of Clinical Oncology2024-06-012 citations